Abstract: Glass articles with coatings are disclosed herein. According to embodiments, a glass article may include a glass body comprising glass and having a first surface and a second surface opposite the first surface, wherein the first surface is an exterior surface of the glass body. A coating disposed on at least a portion of the exterior surface of the glass body. The coated glass article may have an effective throughput rate greater than or equal to 1.10×RT, wherein RT is the effective throughput rate of an uncoated glass article in units of parts per minute (ppm).

Abstract: Low-friction coatings and glass articles with low-friction coatings are disclosed. According to one embodiment, a coated glass article may include a glass body comprising a first surface and a low-friction coating positioned on at least a portion of the first surface of the glass body. The low-friction coating may include a polymer chemical composition. The coated glass article may be thermally stable at a temperature of at least about 260° C. for 30 minutes. A light transmission through the coated glass article may be greater than or equal to about 55% of a light transmission through an uncoated glass article for wavelengths from about 400 nm to about 700 nm. The low-friction coating may have a mass loss of less than about 5% of its mass when heated from a temperature of 150° C. to 350° C. at a ramp rate of about 10° C./minute.

Abstract: Coated pharmaceutical packages are disclosed. The coated pharmaceutical packages may include a glass body comprising a first surface and a second surface opposite the first surface. The glass body may be a glass container formed from a borosilicate glass composition and the first surface is an exterior surface of the glass container. A low-friction coating may be positioned on at least a portion of the first surface of the glass body. In embodiments, the low-friction coating may be a fluoropolymer.

Abstract: Disclosed herein are delamination resistant glass pharmaceutical containers which may include an aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to ISO 720-1985 testing standard. The glass containers may also have a compressive stress layer with a depth of layer of greater than 25 ?m. A surface compressive stress of the glass containers may be greater than or equal to 350 MPa. The delamination resistant glass pharmaceutical containers may be ion exchange strengthened and the ion exchange strengthening may include treating the delamination resistant glass pharmaceutical container in a molten salt bath for a time less than or equal to 5 hours at a temperature less than or equal to 450° C.

Abstract: In embodiments, a delamination resistant glass pharmaceutical package includes a glass body formed from a Type 1 Class glass composition according to ASTM Standard E438-92, the glass body having a wall portion with an inner surface and an outer surface. The glass body may have at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719 and Type 1 chemical durability according to USP <660>. An interior region of the glass body may extend from about 10 nm below the inner surface and having a persistent layer homogeneity. The glass body may also have a surface region extending over the inner surface and having a persistent surface homogeneity such that the glass body is resistant to delamination.

Abstract: Coated pharmaceutical packages are disclosed. In embodiments, a coated pharmaceutical package includes a glass body comprising a first surface. A low-friction coating may be positioned on at least a portion of the first surface of the glass body. The low-friction coating may include a polymer chemical composition. A light transmission through the coated pharmaceutical package may be greater than or equal to about 55% of a light transmission through an uncoated pharmaceutical package for wavelengths from about 400 nm to about 700 nm. The low-friction coating may have a mass loss of less than about 5% of its mass when heated from a temperature of 150° C. to 350° C. at a ramp rate of about 10° C./minute.

Abstract: Shaped glass structures, in particular to curved glass structures, having optically improved transmittance are provided along with methods of making such glass structures. Articles and methods described herein mask tube or reforming defects with help of refractive index-matching substances (e.g. optically clear adhesives) and/or additional glass layers. The articles and methods are applicable to any shaped glass, and is particularly useful for 3D-shaped parts for use in portable electronic devices.

Abstract: Low-friction coatings and glass articles with low-friction coatings are disclosed. According to one embodiment, a coated glass article may include a glass body comprising a first surface and a low-friction coating positioned on at least a portion of the first surface of the glass body. The low-friction coating may include a polymer chemical composition. The coated glass article may be thermally stable at a temperature of at least about 260° C. for 30 minutes. A light transmission through the coated glass article may be greater than or equal to about 55% of a light transmission through an uncoated glass article for wavelengths from about 400 nm to about 700 nm. The low-friction coating may have a mass loss of less than about 5% of its mass when heated from a temperature of 150° C. to 350° C. at a ramp rate of about 10° C./minute.

Abstract: A coated glass pharmaceutical package may include a body formed from borosilicate glass that meets the Type 1 criteria according to USP <660>. The body may have an interior surface and an exterior surface. A low-friction coating having a thickness of less than 100 microns may be positioned on at least a portion of the exterior surface. The portion of the exterior surface with the low-friction coating may have a coefficient of friction that is at least 20% less than an uncoated glass pharmaceutical package formed from the same glass composition and the coefficient of friction may not increase by more than 30% after undergoing a depyrogenation cycle at a temperature of from 250° C. to 400° C. for a time period of from 30 seconds to 72 hours.

Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In another embodiment, a glass composition may include from about 70 mol. % to about 80 mol. % SiO2; from about 3 mol. % to about 13 mol. % alkaline earth oxide; X mol. % Al2O3; and Y mol. % alkali oxide. The alkali oxide may include Na2O in an amount greater than about 8 mol. %. A ratio of Y:X may be greater than 1 and the glass composition may be free of boron and compounds of boron. In some embodiments, the glass composition may also be free of phosphorous and compounds of phosphorous. Glass articles formed from the glass composition may have at least a class S3 acid resistance according to DIN 12116, at least a class A2 base resistance according to ISO 695, and a type HGA1 hydrolytic resistance according to ISO 720.

Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In another embodiment, a glass composition may include from about 70 mol. % to about 80 mol. % SiO2; from about 3 mol. % to about 13 mol. % alkaline earth oxide; X mol. % A12O3; and Y mol. % alkali oxide. The alkali oxide may include Na2O in an amount greater than about 8 mol. %. A ratio of Y:X may be greater than 1 and the glass composition may be free of boron and compounds of boron. In some embodiments, the glass composition may also be free of phosphorous and compounds of phosphorous. Glass articles formed from the glass composition may have at least a class S3 acid resistance according to DIN 12116, at least a class A2 base resistance according to ISO 695, and a type HGA1 hydrolytic resistance according to ISO 720.

Abstract: Coated pharmaceutical packages are disclosed. In embodiments, a coated pharmaceutical package may include a glass body comprising a first surface. A low-friction coating may be positioned on at least a portion of the first surface of the glass body. The low-friction coating may include a polymer chemical composition. The coated pharmaceutical package may be thermally stable at a temperature of at least about 260° C. for 30 minutes. The low-friction coating may have a mass loss of less than about 5% of its mass when heated from a temperature of 150° C. to 350° C. at a ramp rate of about 10° C./minute.

Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In another embodiment, a glass composition may include from about 70 mol. % to about 80 mol. % SiO2; from about 3 mol. % to about 13 mol. % alkaline earth oxide; X mol. % Al2O3; and Y mol. % alkali oxide. The alkali oxide may include Na2O in an amount greater than about 8 mol. %. A ratio of Y:X may be greater than 1 and the glass composition may be free of boron and compounds of boron. In some embodiments, the glass composition may also be free of phosphorous and compounds of phosphorous. Glass articles formed from the glass composition may have at least a class S3 acid resistance according to DIN 12116, at least a class A2 base resistance according to ISO 695, and a type HGA1 hydrolytic resistance according to ISO 720.

Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. According to one embodiment, the glass composition may include greater than or equal to about 68 mol. % SiO2 and less than or equal to about 80 mol. % SiO2; greater than or equal to about 3 mol. % and less than or equal to about 13 mol. % alkaline earth oxide; X mol. % Al2O3, wherein X is greater than or equal to about 4 and less than or equal to about 8; Y mol. % alkali oxide, wherein the alkali oxide comprises Na2O in an amount greater than about 8 mol %; and B2O3, wherein a ratio (B2O3 (mol. %)/(Y mol. %?X mol. %) is greater than 0 and less than 0.3. In some embodiments, the glass composition may be free of phosphorous and compounds of phosphorous.

Abstract: Glass pharmaceutical packages with coatings are disclosed herein. According to one embodiment, the glass pharmaceutical package includes a glass body enclosing an inner volume and having an exterior surface. A coating may be positioned on at least a portion of the exterior surface of the glass body. The coating may include a coupling agent layer having a first thickness of greater than or equal to 25 nm and less than or equal to 100 nm. A polymer layer having a second thickness of less than 50 nm may be positioned over the coupling agent layer.

Abstract: Described herein are various methods and manufacturing methods for making antimicrobial and strengthened, antimicrobial glass articles and substrates. The methods described herein generally include contacting the article with a KNO3-containing molten salt bath set at about 380 C to about 460 C for about 30 minutes to about 24 hours to form a compressive stress layer that extends inward from a surface of the glass substrate to a first depth; and contacting the article comprising the compressive stress layer with a AgNO3-containing molten salt bath set at about 300° C. to about 400° C. for about 5 minutes to about 18 hours to form an antimicrobial region that extends inward from the surface of the glass substrate to a second depth. The methods also include poisoning at least the AgNO3-containing molten salt bath and, in some cases, the KNO3-containing molten salt bath. Poisoning components include Na+ and Li+ ions.

Abstract: A coated glass pharmaceutical package may include a body formed from a Type 1 Class glass according to ASTM Standard E438-92. The body may have an interior surface and an exterior surface. The body may also have at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719 and a Type 1 chemical durability according to USP <660>. A coating having a thickness of ?100 microns may be positioned on at least a portion of the exterior surface. The portion of the exterior surface with the coating may have a coefficient of friction that is at least 20% less than an uncoated glass pharmaceutical package and the coefficient of friction does not increase by more than 30% after undergoing a depyrogenation.

Abstract: According to one embodiment, a coated glass package may include a glass body having a Type 1 chemical durability according to USP 660, a class A2 base resistance or better according to ISO 695, and a type HGB2 hydrolytic resistance or better according to ISO 719. The glass body may include an interior surface and an exterior surface. A lubricous coating having a thickness of ?100 microns may be positioned on the exterior surface. The portion of the exterior surface with the coating may have a coefficient of friction that is at least 20% less than an uncoated glass package and the coefficient of friction does not increase by more than 30% after undergoing depyrogenation. A horizontal compression strength of the coated glass package is at least 10% greater than an uncoated glass package and the horizontal compression strength is not reduced by more than 20% after depyrogenation.

Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In another embodiment, a glass composition may include from about 70 mol. % to about 80 mol. % SiO2; from about 3 mol. % to about 13 mol. % alkaline earth oxide; X mol. % Al2O3; and Y mol. % alkali oxide. The alkali oxide may include Na2O in an amount greater than about 8 mol. %. A ratio of Y:X may be greater than 1 and the glass composition may be free of boron and compounds of boron. In some embodiments, the glass composition may also be free of phosphorous and compounds of phosphorous. Glass articles formed from the glass composition may have at least a class S3 acid resistance according to DIN 12116, at least a class A2 base resistance according to ISO 695, and a type HGA1 hydrolytic resistance according to ISO 720.

Abstract: Delamination resistant glass containers with heat-tolerant coatings are disclosed. In one embodiment, a glass container may include a glass body having an interior surface, an exterior surface and a wall thickness extending from the exterior surface to the interior surface. At least the interior surface of the glass body is delamination resistant. The glass container may further include a heat-tolerant coating positioned on at least a portion of the exterior surface of the glass body. The heat-tolerant coating may be thermally stable at temperatures greater than or equal to 260° C. for 30 minutes.